Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1077 | 1030 | 1143 | 1065 | 1238 | 1925 |
Fund Return | 7.69% | 2.99% | 14.29% | 2.12% | 4.36% | 6.77% |
Place in category | 247 | 181 | 172 | 195 | 163 | 64 |
% in Category | 63 | 43 | 45 | 54 | 56 | 28 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
FC Responsible Global Equity 1 Acc | 1.33B | 5.68 | 5.70 | 11.23 | ||
FC Responsible Global Equity 1 Inc | 1.33B | 5.64 | 5.43 | 11.09 | ||
FC Responsible Global Equity 2 Acc | 1.33B | 5.81 | 6.53 | 12.17 | ||
FC Responsible Global Equity 4 Inc | 1.33B | 5.95 | 7.30 | 12.94 | ||
FC Responsible Global Equity Fund 2 | 1.33B | 11.03 | 2.96 | 12.15 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Liontrust Special Situations Fund R | 34.43M | -1.48 | 2.55 | 6.09 | ||
Liontrust Special Situations Fund A | 5.38M | 4.82 | 0.46 | 7.81 | ||
Liontrust Special Situations Fund I | 2.3B | 1.91 | -0.48 | 7.96 | ||
Artemis UK Select Fund G Inc GBP | 741.61M | 20.04 | 8.70 | - | ||
Artemis UK Select Fund R Acc | 206.3M | 19.01 | 7.59 | 8.68 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
AstraZeneca | GB0009895292 | 7.88 | 10,474.0 | +4.09% | |
Unilever | GB00B10RZP78 | 5.07 | 56.44 | +3.45% | |
Experian | GB00B19NLV48 | 3.15 | 3,809.0 | +2.67% | |
GSK plc | GB00BN7SWP63 | 2.70 | 1,342.00 | +2.48% | |
Ashtead Group | GB0000536739 | 2.65 | 6,332.0 | +2.43% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | BUY | Strong Sell | Strong Buy |
Summary | Buy | Neutral | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review